Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.02
NYSE:RAD's Cash to Debt is ranked lower than
97% of the 375 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.48 vs. NYSE:RAD: 0.02 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:RAD' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.03 Max: 0.27
Current: 0.02
0
0.27
Equity to Asset 0.05
NYSE:RAD's Equity to Asset is ranked lower than
97% of the 370 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. NYSE:RAD: 0.05 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:RAD' s Equity to Asset Range Over the Past 10 Years
Min: -0.38  Med: 0.01 Max: 0.39
Current: 0.05
-0.38
0.39
Interest Coverage 1.52
NYSE:RAD's Interest Coverage is ranked lower than
95% of the 389 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.20 vs. NYSE:RAD: 1.52 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:RAD' s Interest Coverage Range Over the Past 10 Years
Min: 0.02  Med: 1.09 Max: 2.11
Current: 1.52
0.02
2.11
F-Score: 5
Z-Score: 3.01
M-Score: -2.63
WACC vs ROIC
16.89%
4.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 1.96
NYSE:RAD's Operating margin (%) is ranked lower than
63% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.90 vs. NYSE:RAD: 1.96 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:RAD' s Operating margin (%) Range Over the Past 10 Years
Min: -7.81  Med: 1.29 Max: 3.16
Current: 1.96
-7.81
3.16
Net-margin (%) 0.41
NYSE:RAD's Net-margin (%) is ranked lower than
75% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.64 vs. NYSE:RAD: 0.41 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:RAD' s Net-margin (%) Range Over the Past 10 Years
Min: -11.09  Med: -0.63 Max: 7.95
Current: 0.41
-11.09
7.95
ROE (%) 24.88
NYSE:RAD's ROE (%) is ranked higher than
91% of the 371 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.43 vs. NYSE:RAD: 24.88 )
Ranked among companies with meaningful ROE (%) only.
NYSE:RAD' s ROE (%) Range Over the Past 10 Years
Min: -1148.43  Med: -33.1 Max: 51.83
Current: 24.88
-1148.43
51.83
ROA (%) 1.17
NYSE:RAD's ROA (%) is ranked lower than
72% of the 378 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.49 vs. NYSE:RAD: 1.17 )
Ranked among companies with meaningful ROA (%) only.
NYSE:RAD' s ROA (%) Range Over the Past 10 Years
Min: -29.43  Med: -2.28 Max: 26.83
Current: 1.17
-29.43
26.83
ROC (Joel Greenblatt) (%) 17.00
NYSE:RAD's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.53 vs. NYSE:RAD: 17.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:RAD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -44.02  Med: 7.1 Max: 22.13
Current: 17
-44.02
22.13
Revenue Growth (3Y)(%) 1.80
NYSE:RAD's Revenue Growth (3Y)(%) is ranked lower than
64% of the 320 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. NYSE:RAD: 1.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:RAD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.2  Med: -3 Max: 15.4
Current: 1.8
-19.2
15.4
EBITDA Growth (3Y)(%) 4.70
NYSE:RAD's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 289 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.80 vs. NYSE:RAD: 4.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:RAD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.6  Med: -1.9 Max: 24.2
Current: 4.7
-15.6
24.2
EPS Growth (3Y)(%) 10.10
NYSE:RAD's EPS Growth (3Y)(%) is ranked higher than
63% of the 258 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.00 vs. NYSE:RAD: 10.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:RAD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.9  Med: 1.3 Max: 479.9
Current: 10.1
-59.9
479.9
» NYSE:RAD's 10-Y Financials

Financials (Next Earnings Date: 2016-12-15)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

RAD Guru Trades in Q4 2015

Ken Fisher 10,809 sh (New)
Mario Gabelli 717,400 sh (New)
Jeremy Grantham 5,540,600 sh (New)
Eric Mindich 8,203,124 sh (New)
Pioneer Investments 922,139 sh (New)
George Soros 808,700 sh (New)
First Eagle Investment 5,627,170 sh (+12.02%)
Paul Tudor Jones 100,100 sh (unchged)
Larry Robbins Sold Out
Joel Greenblatt 167,539 sh (-93.28%)
» More
Q1 2016

RAD Guru Trades in Q1 2016

John Paulson 263,500 sh (New)
Jim Simons 94,200 sh (New)
Paul Tudor Jones 100,600 sh (New)
Mario Gabelli 1,067,250 sh (+48.77%)
Paul Tudor Jones 100,100 sh (unchged)
Ken Fisher Sold Out
First Eagle Investment Sold Out
Jeremy Grantham Sold Out
Eric Mindich Sold Out
Pioneer Investments 921,305 sh (-0.09%)
George Soros 500,000 sh (-38.17%)
Joel Greenblatt 71,752 sh (-57.17%)
» More
Q2 2016

RAD Guru Trades in Q2 2016

Leucadia National 857,991 sh (New)
Jeremy Grantham 2,382,600 sh (New)
John Burbank 14,678 sh (New)
David Einhorn 10,330,000 sh (New)
Jim Simons 5,295,600 sh (+5521.66%)
John Paulson 580,900 sh (+120.46%)
Mario Gabelli 1,385,875 sh (+29.85%)
Paul Tudor Jones 122,800 sh (unchged)
Joel Greenblatt Sold Out
George Soros Sold Out
Pioneer Investments 919,826 sh (-0.16%)
Paul Tudor Jones 83,605 sh (-16.89%)
» More
Q3 2016

RAD Guru Trades in Q3 2016

Eric Mindich 3,078,000 sh (New)
Paul Singer 3,179,854 sh (New)
Jeremy Grantham 3,889,139 sh (+63.23%)
Pioneer Investments 1,326,427 sh (+44.20%)
Leucadia National 1,208,291 sh (+40.83%)
David Einhorn 13,443,035 sh (+30.14%)
Paul Singer 2,000,000 sh (unchged)
Paul Tudor Jones 122,800 sh (unchged)
Jim Simons Sold Out
John Paulson Sold Out
John Burbank Sold Out
Mario Gabelli 1,369,975 sh (-1.15%)
Paul Tudor Jones 52,162 sh (-37.61%)
» More
» Details

Insider Trades

Latest Guru Trades with RAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Rite Aid Corp

SymbolPriceYieldDescription
RADCO0.000.00Conv Pfd Shs Series -I-

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:OTCPK:RADLY, OTCPK:CLCGY, NYSE:GNC, NAS:PETS, OTCBB:COCP, OTCPK:CWNM, NAS:CJJD, OTCPK:HEWA, NAS:WBA » details
Traded in other countries:RTA.Germany,
Rite Aid Corp operates retail drugstore chains in the United States. As of February 28, 2015, the Company operated 4,570 stores in 31 states across the country and in the District of Columbia.

Rite Aid Corp a Delaware corporation was incorporated in 1968. It operates retail drugstore chain in the United States. The Company operated approximately 4,561 stores in 31 states across the country and in the District of Columbia. Its segments include Retail Pharmacy Segment and New Pharmacy Segment. The Company sells prescription drugs and an assortment of other merchandise, which it calls 'front end' products. Front end products include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise and numerous other convenience products. The Company attempts to distinguish its stores from other national chain drugstores, in part, through its wellness + loyalty program, private brands and its strategic alliance with GNC, a retailer of vitamin and mineral supplements. The retail drugstore industry is competitive. It competes with retail drugstore chains, independently owned drugstores, supermarkets, mass merchandisers, discount stores, wellness offerings, dollar stores and mail order pharmacies. The Company's business is subject to federal, state, and local government laws, regulations and administrative practices.

Top Ranked Articles about Rite Aid Corp

David Einhorn Adds Calpine, Rite Aid, Amaya to Portfolio The guru’s top 3 new holdings
David Einhorn (Trades, Portfolio) of Greenlight Capital acquired three new holdings during the second quarter. They are Calpine Corp. (NYSE:CPN), Rite Aid Corp. (NYSE:RAD) and Amaya Inc. (NASDAQ:AYA). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 61.60
RAD's P/E(ttm) is ranked lower than
92% of the 401 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.79 vs. RAD: 61.60 )
Ranked among companies with meaningful P/E(ttm) only.
RAD' s P/E(ttm) Range Over the Past 10 Years
Min: 1.86  Med: 14.69 Max: 328.5
Current: 61.6
1.86
328.5
PE(NRI) 61.60
RAD's PE(NRI) is ranked lower than
91% of the 322 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.66 vs. RAD: 61.60 )
Ranked among companies with meaningful PE(NRI) only.
RAD' s PE(NRI) Range Over the Past 10 Years
Min: 1.86  Med: 14.69 Max: 219
Current: 61.6
1.86
219
Price/Owner Earnings (ttm) 70.25
RAD's Price/Owner Earnings (ttm) is ranked lower than
85% of the 207 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.40 vs. RAD: 70.25 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
RAD' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.01  Med: 17.16 Max: 547.5
Current: 70.25
3.01
547.5
P/B 13.71
RAD's P/B is ranked lower than
98% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.91 vs. RAD: 13.71 )
Ranked among companies with meaningful P/B only.
RAD' s P/B Range Over the Past 10 Years
Min: 0.29  Med: 2.52 Max: 151.55
Current: 13.71
0.29
151.55
P/S 0.25
RAD's P/S is ranked higher than
74% of the 425 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.51 vs. RAD: 0.25 )
Ranked among companies with meaningful P/S only.
RAD' s P/S Range Over the Past 10 Years
Min: 0.01  Med: 0.1 Max: 0.34
Current: 0.25
0.01
0.34
PFCF 133.48
RAD's PFCF is ranked lower than
96% of the 202 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 22.20 vs. RAD: 133.48 )
Ranked among companies with meaningful PFCF only.
RAD' s PFCF Range Over the Past 10 Years
Min: 1.85  Med: 23.2 Max: 4850
Current: 133.48
1.85
4850
POCF 12.51
RAD's POCF is ranked lower than
57% of the 261 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.83 vs. RAD: 12.51 )
Ranked among companies with meaningful POCF only.
RAD' s POCF Range Over the Past 10 Years
Min: 0.52  Med: 7.79 Max: 84.58
Current: 12.51
0.52
84.58
EV-to-EBIT 24.07
RAD's EV-to-EBIT is ranked lower than
77% of the 422 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.20 vs. RAD: 24.07 )
Ranked among companies with meaningful EV-to-EBIT only.
RAD' s EV-to-EBIT Range Over the Past 10 Years
Min: -2331.6  Med: 20.8 Max: 3760.7
Current: 24.07
-2331.6
3760.7
EV-to-EBITDA 12.92
RAD's EV-to-EBITDA is ranked lower than
57% of the 434 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.57 vs. RAD: 12.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
RAD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.2  Med: 12.3 Max: 17.3
Current: 12.92
-6.2
17.3
PEG 3.62
RAD's PEG is ranked lower than
67% of the 163 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.12 vs. RAD: 3.62 )
Ranked among companies with meaningful PEG only.
RAD' s PEG Range Over the Past 10 Years
Min: 0.16  Med: 1.26 Max: 4.38
Current: 3.62
0.16
4.38
Current Ratio 1.62
RAD's Current Ratio is ranked higher than
68% of the 363 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.22 vs. RAD: 1.62 )
Ranked among companies with meaningful Current Ratio only.
RAD' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.81 Max: 3.11
Current: 1.62
0.81
3.11
Quick Ratio 0.69
RAD's Quick Ratio is ranked lower than
54% of the 363 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.72 vs. RAD: 0.69 )
Ranked among companies with meaningful Quick Ratio only.
RAD' s Quick Ratio Range Over the Past 10 Years
Min: 0.13  Med: 0.46 Max: 1.25
Current: 0.69
0.13
1.25
Days Inventory 41.01
RAD's Days Inventory is ranked lower than
52% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.37 vs. RAD: 41.01 )
Ranked among companies with meaningful Days Inventory only.
RAD' s Days Inventory Range Over the Past 10 Years
Min: 41.01  Med: 63.29 Max: 70.58
Current: 41.01
41.01
70.58
Days Sales Outstanding 20.45
RAD's Days Sales Outstanding is ranked lower than
59% of the 278 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.17 vs. RAD: 20.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
RAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.31  Med: 13.54 Max: 20.45
Current: 20.45
7.31
20.45
Days Payable 24.98
RAD's Days Payable is ranked lower than
80% of the 265 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 45.81 vs. RAD: 24.98 )
Ranked among companies with meaningful Days Payable only.
RAD' s Days Payable Range Over the Past 10 Years
Min: 21.83  Med: 25.85 Max: 29.42
Current: 24.98
21.83
29.42

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.90
RAD's 3-Year Average Share Buyback Ratio is ranked lower than
72% of the 200 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.60 vs. RAD: -4.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RAD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.8  Med: -3.7 Max: -0.3
Current: -4.9
-25.8
-0.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 4.88
RAD's Price/Projected FCF is ranked lower than
88% of the 269 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.46 vs. RAD: 4.88 )
Ranked among companies with meaningful Price/Projected FCF only.
RAD' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.35  Med: 3.58 Max: 10.26
Current: 4.88
1.35
10.26
Price/Median PS Value 2.58
RAD's Price/Median PS Value is ranked lower than
97% of the 417 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.08 vs. RAD: 2.58 )
Ranked among companies with meaningful Price/Median PS Value only.
RAD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.09  Med: 1.37 Max: 8.98
Current: 2.58
0.09
8.98
Price/Peter Lynch Fair Value 4.31
RAD's Price/Peter Lynch Fair Value is ranked lower than
92% of the 113 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.74 vs. RAD: 4.31 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
RAD' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.16  Med: 1.46 Max: 8.43
Current: 4.31
0.16
8.43
Earnings Yield (Greenblatt) (%) 4.19
RAD's Earnings Yield (Greenblatt) (%) is ranked lower than
68% of the 473 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.30 vs. RAD: 4.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RAD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 4.5 Max: 8.2
Current: 4.19
0.3
8.2
Forward Rate of Return (Yacktman) (%) 16.27
RAD's Forward Rate of Return (Yacktman) (%) is ranked higher than
77% of the 228 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.35 vs. RAD: 16.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RAD' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -36.2  Med: 0.5 Max: 55.3
Current: 16.27
-36.2
55.3

More Statistics

Revenue (TTM) (Mil) $32,638
EPS (TTM) $ 0.13
Beta1.64
Short Percentage of Float3.22%
52-Week Range $6.33 - 8.30
Shares Outstanding (Mil)1,052.13

Analyst Estimate

Feb17
Revenue (Mil $)
EPS ($) 0.08
EPS w/o NRI ($) 0.08
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for RAD

Headlines

Articles On GuruFocus.com
Dividend Aristocrats in Focus Part 38: Walgreens Boots Alliance Nov 10 2016 
Why I Am Now Interested in CVS Health Corporation Oct 13 2016 
Rite Aid Is a Solid Risk Arbitrage Trade Sep 27 2016 
Why Walgreens Is a Long-Term Buy Now Sep 09 2016 
David Einhorn Adds Calpine, Rite Aid, Amaya to Portfolio Aug 16 2016 
CVS and Walgreens: A Duopoly That's Hard to Ignore Jul 08 2016 
In Spite of Less Revenue Rite Aid Still Has Growth Potential Jun 21 2016 
Walgreens Boots Alliance: 40 Consecutive Years of Dividend Growth and Counting Jun 17 2016 
Undervalued Stocks With Low PE Mar 24 2016 
Is CVS Pharmacy Undervalued? Feb 22 2016 

More From Other Websites
5 best-performing stocks under $10 since the election Nov 28 2016
Is Rite Aid Corporation (RAD) Worthy of Your Portfolio? Nov 27 2016
Rite Aid (RAD) Focuses on Strategic Growth: Time to Hold? Nov 25 2016
Rite Aid Presents Black Friday Shoppers With Lowest Offers of the Year Nov 21 2016
ETFs with exposure to Rite Aid Corp. : November 17, 2016 Nov 17 2016
Momentum bulls chase Rite Aid Nov 17 2016
Rite Aid Corp. breached its 50 day moving average in a Bullish Manner : RAD-US : November 16, 2016 Nov 16 2016
What’s Next for the WBA-RAD Deal? Nov 14 2016
Will the WBA-RAD Deal Clear FTC Hurdles? Nov 14 2016
Where Does Walgreens’s Deal with Rite Aid Stand a Year Later? Nov 14 2016
Rite Aid Customers Can Now Use American Express® Membership Rewards® Points for Purchases at Rite... Nov 14 2016
Rite Aid Customers Can Now Use American Express® Membership Rewards® Points for Purchases at Rite... Nov 14 2016
Dividend Aristocrats in Focus Part 38: Walgreens Boots Alliance Nov 10 2016
[$$] Walgreens CEO Picks Up Stock as KKR Quits Nov 10 2016
Shares of Pharmacy Benefit Managers Cheer Trump Presidency, Though Uncertainty Remains Nov 09 2016
CVS Health Dives On Sales Miss, Earnings Guidance; Walgreens Falls Nov 08 2016
7 Binary Trades For The End Of 2016 Nov 08 2016
5 Stocks to Watch Before the Market Opens on Election Day Nov 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)